1. Home
  2. DH vs TNXP Comparison

DH vs TNXP Comparison

Compare DH & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DH
  • TNXP
  • Stock Information
  • Founded
  • DH 2011
  • TNXP 2007
  • Country
  • DH United States
  • TNXP United States
  • Employees
  • DH 782
  • TNXP N/A
  • Industry
  • DH Computer Software: Prepackaged Software
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • DH Technology
  • TNXP Health Care
  • Exchange
  • DH Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • DH 332.0M
  • TNXP 335.6M
  • IPO Year
  • DH 2021
  • TNXP N/A
  • Fundamental
  • Price
  • DH $3.20
  • TNXP $22.43
  • Analyst Decision
  • DH Hold
  • TNXP Buy
  • Analyst Count
  • DH 5
  • TNXP 1
  • Target Price
  • DH $4.35
  • TNXP $70.00
  • AVG Volume (30 Days)
  • DH 342.8K
  • TNXP 1.1M
  • Earning Date
  • DH 11-06-2025
  • TNXP 11-11-2025
  • Dividend Yield
  • DH N/A
  • TNXP N/A
  • EPS Growth
  • DH N/A
  • TNXP N/A
  • EPS
  • DH N/A
  • TNXP N/A
  • Revenue
  • DH $244,926,000.00
  • TNXP $9,831,000.00
  • Revenue This Year
  • DH N/A
  • TNXP $14.79
  • Revenue Next Year
  • DH $0.68
  • TNXP $933.49
  • P/E Ratio
  • DH N/A
  • TNXP N/A
  • Revenue Growth
  • DH N/A
  • TNXP N/A
  • 52 Week Low
  • DH $2.15
  • TNXP $6.76
  • 52 Week High
  • DH $5.68
  • TNXP $130.00
  • Technical
  • Relative Strength Index (RSI)
  • DH 32.45
  • TNXP 30.37
  • Support Level
  • DH $3.16
  • TNXP $22.21
  • Resistance Level
  • DH $4.06
  • TNXP $29.19
  • Average True Range (ATR)
  • DH 0.20
  • TNXP 1.56
  • MACD
  • DH -0.09
  • TNXP 0.10
  • Stochastic Oscillator
  • DH 4.20
  • TNXP 3.72

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: